日报更新时间：
周报更新时间：04-18 04:06
今开价：9.33
最高价：9.56
成交量：490422.0
昨收价：9.44
最低价：9.2
最新价：9.505
英文名称：Karyopharm Therapeutics
行业：医疗
简介：Karyopharm Therapeutics Inc.是一家专注于研发新式一期核运输癌症治疗方法的临床型制药公司
电话：1-617-6580600
Karyopharm Therapeutics是一家临床阶段的制药公司，总部位于美国马萨诸塞州的牛顿市，专注于新型一流药物的发现，开发和商业化，这些药物主要针对核转运，用于治疗癌症和其他主要疾病。Karyopharm是口服选择性核输出抑制剂（SINE）技术的行业领导者，该技术旨在通过抑制输出，特别是XPO1来解决肿瘤发生的中心机制。Karyopharm的主要候选产品——Selinexor(KPT-330)已在世界范围内进行血液系统恶性肿瘤或实体瘤患者的临床试验治疗。Selinexor目前处于： 治疗难治性多发性骨髓瘤的 IIb 期临床研究阶段； 结合骨髓治疗治疗多发性骨髓瘤的 Ib/II 期临床研究阶段； 结合Velcade（硼替佐米）和地塞米松治疗多发性骨髓瘤的 III 期临床试验阶段； 治疗弥漫性大B细胞淋巴瘤的 IIb 期临床研究阶段； 治疗脂肪肉瘤的II / III期临床研究阶段； 治疗子宫内膜癌的 III 期临床试验阶段； 治疗多形性胶质母细胞瘤的 II 期临床试验阶段。Karyopharm目前正准备在2019年首次在美国进行Selinexor的商业发布。除了selinexor之外，Karyopharm还推出了一系列新型口服候选药物，包括： Eltanexor（KPT-8602），治疗骨髓增生异常综合征，结肠直肠癌和去势抵抗性前列腺癌；处于治疗复发/难治性多发性骨髓瘤的 I/II 期临床试验阶段。 Verdinexor（KPT-335），作为抗病毒药物，作为伴侣动物癌症的潜在的治疗方法，目前处于 IIb 期临床试验阶段； KPT-9274，一种双重PAK4 / NAMPT抑制剂，用于治疗晚期实体恶性肿瘤或非霍奇金淋巴瘤，目前处于 I 期临床试验阶段； KPT-350，处于临床前阶段，用于治疗神经系统疾病，炎症和自身免疫性疾病。
| 交易日期 | 交易人 | 职位 | 类型 | 交易份额 | 价格 |
|---|---|---|---|---|---|
| 2016-11-13 | Frenkel (Ran) | Officer | Sell | 3309 | 10.06 |
| 2016-11-08 | Primiano Christopher Brett | General Counsel | Sell | 4342 | 8.19 |
| 2016-11-08 | Renz (Justin A) | Chief Financial Officer | Sell | 4342 | 8.19 |
| 2016-11-04 | Frenkel (Ran) | Officer | Buy | 15000 | -- |
| 2016-11-04 | Primiano Christopher Brett | General Counsel | Buy | 15000 | -- |
| 2016-11-04 | Renz (Justin A) | Chief Financial Officer | Buy | 15000 | -- |
| 2016-06-22 | Chione, Ltd. | Beneficial Owner of More than 10% Class | Sell | 18824 | 8.03 |
| 2016-06-12 | Chione, Ltd. | Beneficial Owner of More than 10% Class | Sell | 7074 | 8.51 |
| 2016-06-08 | Chione, Ltd. | Beneficial Owner of More than 10% Class | Sell | 30000 | 9.14 |
| 2016-06-07 | Chione, Ltd. | Beneficial Owner of More than 10% Class | Sell | 15541 | 9.34 |
| 2016-06-06 | Chione, Ltd. | Beneficial Owner of More than 10% Class | Sell | 20000 | 9.25 |
| 2016-06-05 | Chione, Ltd. | Beneficial Owner of More than 10% Class | Sell | 20000 | 9.22 |
| 2016-06-01 | Chione, Ltd. | Beneficial Owner of More than 10% Class | Sell | 17855 | 9.65 |
| 2016-05-31 | Chione, Ltd. | Beneficial Owner of More than 10% Class | Sell | 17568 | 9.64 |
| 2016-05-30 | Chione, Ltd. | Beneficial Owner of More than 10% Class | Sell | 17096 | 9.66 |
| 2016-05-26 | Chione, Ltd. | Beneficial Owner of More than 10% Class | Sell | 40000 | 9.58 |
| 2016-05-25 | Chione, Ltd. | Beneficial Owner of More than 10% Class | Sell | 18182 | 9.59 |
| 2016-05-24 | Chione, Ltd. | Beneficial Owner of More than 10% Class | Sell | 27940 | 9.83 |
| 2016-05-22 | Chione, Ltd. | Beneficial Owner of More than 10% Class | Sell | 33932 | 8.77 |
| 2016-05-19 | Chione, Ltd. | Beneficial Owner of More than 10% Class | Sell | 40000 | 8.52 |
| 2016-05-18 | Chione, Ltd. | Beneficial Owner of More than 10% Class | Sell | 20000 | 8.18 |
| 2016-05-17 | Chione, Ltd. | Beneficial Owner of More than 10% Class | Sell | 30000 | 8.15 |
| 2016-05-16 | Chione, Ltd. | Beneficial Owner of More than 10% Class | Sell | 33800 | 8.15 |
| 2016-05-15 | Chione, Ltd. | Beneficial Owner of More than 10% Class | Sell | 10000 | 8.01 |
| 2016-05-12 | Chione, Ltd. | Beneficial Owner of More than 10% Class | Sell | 400 | 8.01 |
| 2016-05-10 | Chione, Ltd. | Beneficial Owner of More than 10% Class | Sell | 11868 | 8.41 |
| 2016-05-09 | Chione, Ltd. | Beneficial Owner of More than 10% Class | Sell | 20000 | 8.14 |
| 2015-12-29 | Kauffman (Michael G) | Chief Executive Officer | Gift | 3144 | -- |
| 2015-12-29 | Shacham (Sharon) | President | Gift | 3144 | -- |
| 2015-12-29 | Kauffman (Michael G) | Chief Executive Officer | Gift | 3144 | -- |
| 第 页, 共 2 页 首页 上页 下页 末页 | |||||
| 机构持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| Northern Trust Investments Inc | 963864 | 1.58% | 11740 | 1.23% | 2019-07-31 |
| Candriam Luxembourg S.C.A. | 1866778 | 3.07% | 74234 | 4.14% | 2019-03-31 |
| BlackRock Fund Advisors | 2608741 | 4.29% | -33309 | -1.26% | 2019-07-31 |
| Vanguard Group Inc | 2614272 | 4.30% | 885385 | 51.21% | 2019-03-31 |
| Millennium Management LLC | 2719714 | 4.47% | 2272107 | 507.61% | 2019-03-31 |
| BlackRock Inc | 4178808 | 6.87% | -79104 | -1.86% | 2019-03-31 |
| Consonance Capital Management LP | 5158884 | 8.48% | 348806 | 7.25% | 2019-03-31 |
| Palo Alto Investors, LLC | 5262263 | 8.65% | 576911 | 12.31% | 2019-03-31 |
| Wellington Management Company LLP | 8437359 | 13.86% | 220578 | 2.68% | 2019-03-31 |
| Candriam Belgium | 1815500 | 2.98% | -- | -- | 2019-07-31 |
| Citadel Advisors Llc | 1792404 | 2.94% | 1540334 | 611.07% | 2019-03-31 |
| Vanguard Investments Australia Ltd | 1761143 | 2.89% | -62 | -- | 2019-07-31 |
| Fidelity Management and Research Company | 1533800 | 2.52% | -341340 | -18.20% | 2019-03-31 |
| FMR Inc | 1533800 | 2.52% | -341340 | -18.20% | 2019-03-31 |
| Emerald Advisers, LLC | 1508094 | 2.48% | 51621 | 3.54% | 2019-03-31 |
| Emerald Mutual Fund Advisers Trust | 1376475 | 2.26% | 3038 | 0.22% | 2019-03-31 |
| Dimensional Fund Advisors, Inc. | 1129958 | 1.86% | 456184 | 67.71% | 2019-03-31 |
| Hartford Funds Management Company, LLC | 1120133 | 1.84% | -- | -- | 2019-07-31 |
| Fidelity SelectCo, LLC | 1066743 | 1.75% | -251540 | -19.08% | 2019-07-31 |
| Dimensional Fund Advisors LP | 965912 | 1.59% | 4376 | 0.46% | 2019-07-31 |
| State Street Corporation | 963678 | 1.58% | -1559697 | -61.81% | 2019-03-31 |
| Ridgeback Capital Investments L.p. | 3945200 | 6.48% | 3945200 | -- | 2018-12-31 |
| BlackRock Asset Management Canada Ltd | 1216848 | 2.00% | 411 | 0.03% | 2019-05-31 |
| Candriam Luxembourg | 1866778 | 3.07% | 74234 | 4.14% | 2019-03-31 |
| Geode Capital Management, LLC | 1115854 | 1.83% | 584285 | 109.92% | 2018-12-31 |
| Point72 Asset Management, L.P. | 1541718 | 2.53% | 691225 | 81.27% | 2018-12-31 |
| Franklin Advisers, Inc. | 1784696 | 2.93% | -40317 | -2.21% | 2018-12-31 |
| Franklin Resources Inc | 1799696 | 2.96% | -40317 | -2.19% | 2018-12-31 |
| SSGA Funds Management Inc | 1603426 | 2.63% | -9362 | -0.58% | 2019-02-28 |
| TIAA-CREF Investment Management LLC | 1042116 | 1.72% | 471117 | 82.51% | 2018-09-30 |
| BlackRock Institutional Trust Company NA | 1330245 | 2.19% | 503105 | 60.82% | 2018-06-30 |
| Northern Trust Corp | 601974 | 0.99% | 204680 | 51.52% | 2018-06-30 |
| Two Sigma Investments LLC | 504809 | 0.83% | 382921 | 314.16% | 2018-06-30 |
| Emerald Advisers Inc | 561317 | 0.93% | 561317 | -- | 2018-06-30 |
| Northern Trust Investments N A | 601228 | 0.99% | 203934 | 51.33% | 2018-06-30 |
| Franklin Advisers Inc | 2082756 | 3.44% | 51272 | 2.52% | 2018-06-30 |
| State Street Corp | 2337707 | 3.86% | 1348776 | 136.39% | 2018-06-30 |
| Chione Ltd. | 8549920 | 17.26% | -- | -- | 2017-12-31 |
| Private Capital Advisors, Inc. | 416900 | 0.69% | 416900 | -- | 2018-06-30 |
| Schonfeld Strategic Advisors LLC | 415600 | 0.69% | 52708 | 14.52% | 2018-06-30 |
| Delaware Management Business Trust | 338000 | 0.56% | 338000 | -- | 2018-06-30 |
| Teachers Advisors Inc | 332678 | 0.55% | -101759 | -23.42% | 2018-06-30 |
| Delaware Management Company | 338000 | 0.56% | -- | -- | 2018-06-30 |
| Frontier Capital Management CO Inc | 307035 | 0.51% | 307035 | -- | 2018-06-30 |
| venBio Select Advisor LLC | 560658 | 1.13% | 560658 | -- | 2018-03-31 |
| Delphi Management Partners VIII, LLC | 2263006 | 4.80% | -- | -- | 2017-04-28 |
| Iguana Healthcare Management, LLC | 300000 | 0.61% | -100000 | -25.00% | 2017-12-31 |
| J.P. Morgan Investment Management Inc | 292000 | 0.59% | -15200 | -4.95% | 2017-12-31 |
| Baker Bros Advisors LP | 216990 | 0.44% | -- | -- | 2017-12-31 |
| Tekla Capital Management LLC | 756679 | 1.60% | -- | -- | 2017-09-30 |
| TFS Capital LLC | 146819 | 0.37% | 130066 | 776.37% | 2016-10-31 |
| BlackRock Advisors LLC | 101972 | 0.26% | 1907 | 1.91% | 2016-09-30 |
| Mutual Of America Capital Management LLC | 87030 | 0.21% | -436 | -0.50% | 2016-12-31 |
| J. P. Morgan Chase Bank NA | 82400 | 0.21% | -479 | -0.58% | 2016-09-30 |
| Rhumbline Advisers | 81580 | 0.21% | 17120 | 26.56% | 2016-09-30 |
| Deutsche Asset Mgmt Invst Gesenschaft | 78430 | 0.20% | 274 | 0.35% | 2016-09-30 |
| Sharon Shacham, Ph.D., M.B.A. | 2047662 | 2.00% | 55819266 | 0.10% | 1999-11-30 |
| Michael G. Kauffman, M.D., Ph.D. | 2047662 | 2.00% | 55819266 | 0.10% | 1999-11-30 |
| Deepika R. Pakianathan, Ph.D. | 2271524 | 2.00% | 61921744 | 0.10% | 1999-11-30 |
| Entities Affiliated with Franklin Resources, Inc. | 4652759 | 2.00% | 126834210 | 0.10% | 1999-11-30 |
| Entities Affiliated with FMR LLC | 4905084 | 2.00% | 133712590 | 0.20% | 1999-11-30 |
| 共同基金持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| iShares Russell 2000 Growth ETF | 534232 | 0.88% | 10726 | 2.05% | 2019-07-30 |
| Vanguard Total Stock Market Index Fund | 1750506 | 2.88% | -- | -- | 2019-06-30 |
| iShares Russell 2000 ETF | 1260009 | 2.07% | 2464 | 0.20% | 2019-07-30 |
| Wellington Global Health Care Equity | 879921 | 1.45% | 1010 | 0.11% | 2019-03-31 |
| Emerald Growth Fund | 833486 | 1.37% | -- | -- | 2019-06-30 |
| Vanguard Extended Market Index Fund | 710246 | 1.17% | 3092 | 0.44% | 2019-06-30 |
| iShares Nasdaq Biotechnology ETF | 601261 | 0.99% | 6474 | 1.09% | 2019-07-30 |
| Pru Ret Small Cap Growth/Emerald SP | 188031 | 0.31% | -- | -- | 2019-06-30 |
| Hartford Healthcare Fund | 457189 | 0.75% | -- | -- | 2019-06-30 |
| DFA US Small Cap Portfolio | 446991 | 0.73% | -- | -- | 2019-05-31 |
| Delaware Healthcare Fund | 380000 | 0.62% | -- | -- | 2019-06-30 |
| Principal SmallCap Growth Fund I | 276139 | 0.45% | 755 | 0.27% | 2019-06-30 |
| AST Small-Cap Growth Portfolio | 267472 | 0.44% | -- | -- | 2019-06-30 |
| Mutual of America Small Cap Growth Fund | 209029 | 0.34% | 83415 | 66.41% | 2019-03-31 |
| State Street Russell Small Cap | 199195 | 0.33% | -- | -- | 2019-06-30 |
| Fidelity | 193526 | 0.32% | 21133 | 12.26% | 2019-04-30 |
| State Street Russell Small/Mid Cap | 192581 | 0.32% | -- | -- | 2019-06-30 |
| Candriam Eqs L Biotechnology | 1815500 | 2.98% | -- | -- | 2019-06-30 |
| NT R2000 Growth Index Fund - Non-Lending | 194516 | 0.32% | 7737 | 4.14% | 2019-03-31 |
| iShares US Small Cap ETF (CAD-Hedged) | 1015500 | 1.67% | -1701 | -0.17% | 2019-05-30 |
| TIAA-CREF Quant Small-Cap Equity Fund | 249204 | 0.41% | -2800 | -1.11% | 2019-03-31 |
| NT R2000 Index Fund - NL | 187430 | 0.31% | 7336 | 4.07% | 2019-03-31 |
| CREF Stock Account | 200051 | 0.33% | -66840 | -25.04% | 2019-02-28 |
| Hartford Small Company HLS Fund | 181083 | 0.30% | -- | -- | 2019-02-28 |
| Franklin Biotechnology Discovery Fund | 463154 | 0.76% | -- | -- | 2019-01-31 |
| Franklin Small Cap Growth Fund | 547757 | 0.90% | -- | -- | 2019-01-31 |
| Wellington Global Healthcare Equity Fund | 878911 | 1.44% | -22150 | -2.46% | 2018-12-31 |
| SPDR | 1558898 | 2.56% | -9522 | -0.61% | 2019-02-28 |
| Hartford Small Company Fund | 155735 | 0.26% | -- | -- | 2019-01-31 |
| Fidelity Advisor | 197640 | 0.33% | -- | -- | 2018-11-30 |
| Federated MDT Small Cap Core Fund | 150389 | 0.25% | 150389 | -- | 2018-09-30 |
| JHancock Seaport Long/Short Fund | 157980 | 0.26% | -- | -- | 2018-09-30 |
| Tekla World Healthcare Fund | 200324 | 0.33% | -- | -- | 2017-09-30 |
| TEKLA HEALTHCARE OPPORTUNITIES FUND | 300000 | 0.49% | -- | -- | 2017-09-30 |
| JHancock Seaport A | 157980 | 0.26% | 12000 | 8.22% | 2018-07-31 |
| Schwab US Small-Cap ETF | 137081 | 0.20% | -- | -- | 2018-09-13 |
| Hartford Small Company A | 143313 | 0.24% | -- | -- | 2018-07-31 |
| iShares Micro-Cap | 130073 | 0.19% | -- | -- | 2018-09-12 |
| iShares Nasdaq Biotechnology | 683365 | 1.00% | -1302 | -0.19% | 2018-09-12 |
| Hartford Small Company HLS IA | 174397 | 0.29% | -1200 | -0.68% | 2018-07-31 |
| TIAA-CREF Small-Cap Equity Instl | 236100 | 0.39% | -- | -- | 2018-07-31 |
| Vanguard Total Stock Mkt Idx | 1386857 | 2.29% | -- | -- | 2018-07-31 |
| Franklin Small Cap Growth A | 767086 | 1.27% | -- | -- | 2018-07-31 |
| Vanguard Extended Market Idx Inv | 658370 | 1.09% | 5500 | 0.84% | 2018-07-31 |
| CREF Stock R1 | 517357 | 0.86% | -30010 | -5.48% | 2018-07-31 |
| Hartford Healthcare A | 470304 | 0.78% | -- | -- | 2018-07-31 |
| Franklin Biotechnology Discovery A | 463154 | 0.77% | -- | -- | 2018-07-31 |
| iShares Russell 2000 Growth | 423188 | 0.62% | -408 | -0.10% | 2018-09-12 |
| Delaware Healthcare A | 338000 | 0.56% | -- | -- | 2018-07-31 |
| Emerald Growth A | 287711 | 0.48% | -- | -- | 2018-07-31 |
| Fidelity Spartan | 243073 | 0.40% | -- | -- | 2018-07-31 |
| JHVIT Small Cap Growth NAV | 128743 | 0.21% | 85743 | 199.40% | 2018-06-30 |
| Northern Trust Russell 2000 Index Fund - DC - Non-Lending | 119093 | 0.20% | 33213 | 38.67% | 2018-06-30 |
| Mutual of America Small Cap Growth | 144012 | 0.29% | -- | -- | 2018-03-31 |
| USAA Science & Technology | 104870 | 0.17% | 23200 | 28.41% | 2018-05-31 |
| Hartford Healthcare HLS IA | 102878 | 0.17% | 23000 | 28.79% | 2018-05-31 |
| Vanguard Health Care ETF | 101416 | 0.17% | 24954 | 32.64% | 2018-05-31 |
| iShares Russell 2000 Value | 312819 | 0.53% | -516 | -0.16% | 2018-06-21 |
| Principal SmallCap Growth I Instl | 92181 | 0.15% | 91160 | 8928.50% | 2018-05-31 |
| Vanguard Instl Ttl Stk Mkt Idx InstlPls | 86396 | 0.14% | 14000 | 19.34% | 2018-05-31 |
| Met Invt Ser WMC Large Cap Rsrch A | 91751 | 0.18% | -- | -- | 2018-03-31 |
| BioShares | 83135 | 0.13% | -- | -- | 2018-06-08 |
| AST Small Cap Value | 83100 | 0.17% | -27400 | -24.80% | 2018-03-31 |
| NVIT Multi-Manager Small Cap Val IV | 81700 | 0.16% | -2300 | -2.74% | 2018-02-28 |
| Tekla Life Sciences Investors | 256355 | 0.54% | -- | -- | 2017-09-30 |
| State Street Russell Small/Mid Cap Idx Fd Cl I | 99039 | 0.21% | 2373 | 2.45% | 2017-06-30 |
| DFA US Small Cap I | 73020 | 0.15% | -- | -- | 2017-11-30 |
| JPMorgan US Small Company Instl | 157100 | 0.38% | 3900 | 2.55% | 2016-12-31 |
| TFS Market Neutral | 133088 | 0.34% | 116335 | 694.41% | 2016-10-31 |
| Fidelity Advisor® Biotechnology Fund | 1155857 | 3.20% | -- | -- | 2015-10-31 |
| Franklin Biotechnology Discovery | 1052068 | 3.00% | -- | -- | 2015-07-31 |
| Franklin US Opportunities | 920493 | 2.60% | -3835 | -0.40% | 2015-06-30 |
| Fidelity® OTC Portfolio | 619300 | 1.70% | -- | -- | 2015-10-31 |
| Pictet-Biotech | 399571 | 1.40% | -53571 | -11.80% | 2014-09-30 |
| iShares Russell 2000 (AU) | 380494 | 1.50% | -234 | -0.10% | 2015-11-27 |
| Franklin Growth Opportunities Fund | 223481 | 0.60% | -- | -- | 2015-09-30 |
| Franklin Small-Mid Cap Growth Fund | 219300 | 0.60% | -21000 | -8.70% | 2015-09-30 |
| Fidelity® Select Biotechnology Portfolio | 3571115 | 10.00% | -- | -- | 2015-10-31 |
| Cambridge Global Equity Corporate Class | 200000 | 0.60% | -- | -- | 2015-03-31 |
| Garen G. Bohlin | Garen G. Bohlin is on the board of Proteon Therapeutics, Inc., Collegium Pharmaceutical, Inc., Tetraphase Pharmaceuticals, Inc. and Karyopharm Therapeutics, Inc. In his past career Mr. Bohlin occupied the position of Chairman at SpringLeaf Therapeutics, Inc., Partner at Arthur Andersen LLP, Executive Vice President of Constellation Pharmaceuticals, Inc., President & Chief Executive Officer at Bioverativ Therapeutics, Inc., Chief Operating Officer of Sirtris Pharmaceuticals, Inc. and Executive Vice President for Genetics Institute LLC. He received an undergraduate degree from the University of Illinois. |
|---|---|
| Ran Frenkel | Ran Frenkel founded Pfc Pharma Focus Israel Ltd. Mr. Frenkel is Chief Development Operations Officer at Karyopharm Therapeutics, Inc. and Vice President-Business Development of 2P2D Solutions Ltd. Mr. Frenkel previously occupied the position of Chief Executive Officer at Pfc Pharma Focus Israel Ltd., Managing Director-EMEA at Clinipace, Inc. and Managing Director at Actelion Pharmaceuticals US, Inc. He received an undergraduate degree from The Hebrew University of Jerusalem. |
| Barry E. Greene | Barry E. Greene is President of Alnylam Pharmaceuticals, Inc. He is also on the board of Acorda Therapeutics, Inc. and Karyopharm Therapeutics, Inc. and Chief Medical Officer at Vicarious Surgical, Inc. In his past career he was Partner at Andersen Consulting LLP (GB), Vice President-Marketing & Customer Services at AstraZeneca Plc and Vice President-Strategic Integration at AstraZeneca Pharmaceuticals LP (a subsidiary of AstraZeneca Plc), General Manager-Oncology Division at Takeda Oncology Co., Chief Business Officer & Executive Vice President at Mediconsult.com, Inc. and Partner at Accenture Ltd. Barry E. Greene received an undergraduate degree from the University of Pittsburgh. |
| Ran Frenkel | Ran Frenkel founded Pfc Pharma Focus Israel Ltd. Mr. Frenkel is Chief Development Operations Officer at Karyopharm Therapeutics, Inc. and Vice President-Business Development of 2P2D Solutions Ltd. Mr. Frenkel previously occupied the position of Chief Executive Officer at Pfc Pharma Focus Israel Ltd., Managing Director-EMEA at Clinipace, Inc. and Managing Director at Actelion Pharmaceuticals US, Inc. He received an undergraduate degree from The Hebrew University of Jerusalem. |
| Ran Frenkel | Ran Frenkel founded Pfc Pharma Focus Israel Ltd. Mr. Frenkel is Chief Development Operations Officer at Karyopharm Therapeutics, Inc. and Vice President-Business Development of 2P2D Solutions Ltd. Mr. Frenkel previously occupied the position of Chief Executive Officer at Pfc Pharma Focus Israel Ltd., Managing Director-EMEA at Clinipace, Inc. and Managing Director at Actelion Pharmaceuticals US, Inc. He received an undergraduate degree from The Hebrew University of Jerusalem. |
| Tanya N. Lewis | Currently, Tanya N. Lewis is Senior Vice President-Regulatory Affairs at Karyopharm Therapeutics, Inc. In her past career she held the position of VP-Regulatory Affairs & Quality Assurance at Vion Pharmaceuticals, Inc., VP-Regulatory Affairs & Quality Assurance at Idera Pharmaceuticals, Inc., VP-Regulatory Affairs & Quality Assurance at Seaside Therapeutics, Inc., VP-Regulatory Affairs & Quality Assurance at TESARO, Inc. and Senior Director-Regulatory Affairs at Takeda Oncology Co. Tanya N. Lewis received a graduate degree from Massachusetts College of Art & Design and an undergraduate degree from Northeastern University. |
| J. Scott Garland | Currently, J. Scott Garland occupies the position of President, Chief Executive Officer & Director at Portola Pharmaceuticals, Inc. He is also on the board of Karyopharm Therapeutics, Inc. In the past he occupied the position of Chief Commercial Officer & Executive VP for Exelixis, Inc., Head-Sales & Marketing Division at Amgen, Inc., President for Relypsa, Inc. and Vice President-Avastin Franchise at Genentech, Inc. He received an undergraduate degree from California Polytechnic State University (San Luis Obispo) and an MBA from The Fuqua School of Business. |
| Christopher B. Primiano | Christopher B. Primiano holds the position of Secretary, Chief Business Officer & EVP at Karyopharm Therapeutics, Inc. In the past he was Secretary & General Counsel of GlassHouse Technologies, Inc. and Legal Counsel at Wilmer Cutler Pickering Hale & Dorr LLP. He received an undergraduate degree from Georgetown University, a graduate degree from Boston College Law School and an MBA from Wallace E Carroll School of Management. |
| Michael G. Kauffman | Michael G. Kauffman founded Karyopharm Therapeutics, Inc. He is Chief Executive Officer & Director at this company. He is also on the board of Infinity Pharmaceuticals, Inc., Verastem, Inc. and Kezar Life Sciences, Inc. In his past career he was President & Chief Executive Officer for EPIX Pharmaceuticals, Inc. and President & Chief Executive Officer at Predix Pharmaceuticals, Inc. (a subsidiary of EPIX Pharmaceuticals, Inc.), Medical Director of Biogen, Inc., Science Advisor at Deer Management Co. LLC and Operating Partner at Bessemer Venture Partners LP (a subsidiary of Deer Management Co. LLC), Chief Medical Officer for Onyx Pharmaceuticals, Inc., Chief Medical Officer for Proteolix, Inc., Vice President-Medicine at Takeda Oncology Co. and Executive Vice President-Distribution Operations at The Jones Group, Inc. Dr. Kauffman received an undergraduate degree from Amherst College and a doctorate from The Johns Hopkins University School of Medicine. |
| Deepa R. Pakianathan | Dr. Deepa R. Pakianathan is an Independent Non-Executive Director at Mereo BioPharma Group Plc, an Independent Director at Alder Biopharmaceuticals, Inc., an Independent Director at Karyopharm Therapeutics, Inc., an Independent Director at Calithera Biosciences, Inc., a General Partner at Delphi Ventures, Inc., a Managing Member at Delphi Management Partners VII LLC, a Managing Member at Delphi Management Partners VIII LLC and a Managing Member at Delphi Ventures III LP. She is on the Board of Directors at Mereo BioPharma Group Plc, Alder Biopharmaceuticals, Inc., Karyopharm Therapeutics, Inc., Calithera Biosciences, Inc., National Venture Capital Association and San Francisco Conservatory of Music. Dr. Pakianathan was previously employed as an Independent Director by OncoMed Pharmaceuticals, Inc., an Independent Director by Alexza Pharmaceuticals, Inc., a Senior Biotechnology Banker by J.P. Morgan Partners LLC, a Research Analyst by Genesis Merchant Group Securities LLC, a Vice President by J.P. Morgan & Co. Ltd., and a Postdoctoral Scientist by Genentech, Inc. She also served on the board at PTC Therapeutics, Inc., NeurAxon, Inc., Relypsa, Inc., Phenomix Corp., Adiana, Inc., Antipodean Pharmaceuticals, Inc., Ilypsa, Inc. and Proteolix, Inc. She received her undergraduate degree from the University of Mumbai, a graduate degree from the Advanced Centre for Treatment Research & Education in Cancer, a graduate degree from Wake Forest University and a doctorate degree from Wake Forest University. |
| Michael G. Kauffman | Michael G. Kauffman founded Karyopharm Therapeutics, Inc. He is Chief Executive Officer & Director at this company. He is also on the board of Infinity Pharmaceuticals, Inc., Verastem, Inc. and Kezar Life Sciences, Inc. In his past career he was President & Chief Executive Officer for EPIX Pharmaceuticals, Inc. and President & Chief Executive Officer at Predix Pharmaceuticals, Inc. (a subsidiary of EPIX Pharmaceuticals, Inc.), Medical Director of Biogen, Inc., Science Advisor at Deer Management Co. LLC and Operating Partner at Bessemer Venture Partners LP (a subsidiary of Deer Management Co. LLC), Chief Medical Officer for Onyx Pharmaceuticals, Inc., Chief Medical Officer for Proteolix, Inc., Vice President-Medicine at Takeda Oncology Co. and Executive Vice President-Distribution Operations at The Jones Group, Inc. Dr. Kauffman received an undergraduate degree from Amherst College and a doctorate from The Johns Hopkins University School of Medicine. |
| Sharon Shacham | Founder of Karyopharm Therapeutics, Inc. and Predix Pharmaceuticals, Inc., Sharon Shacham currently is President & Chief Scientific Officer at Karyopharm Therapeutics, Inc. She previously was Senior Vice President-Drug Development at EPIX Pharmaceuticals, Inc. and Director-Algorithm & Software Development at Predix Pharmaceuticals, Inc. (a subsidiary of EPIX Pharmaceuticals, Inc.). Dr. Shacham received an undergraduate degree, a doctorate and an MBA from Tel-Aviv University. |
| Cameron Peters | Cameron Peters is Vice President-Finance & Assistant Treasurer at Karyopharm Therapeutics, Inc. Mr. Peters previously held the position of Chief Financial Officer at 24M Technologies, Inc., Senior Consultant at Strategic Decisions Group, Vice President-Finance of Luminus Devices, Inc. and Director-Financial Planning at Takeda Oncology Co. He received a graduate degree from Stanford University, an MBA from Stanford Graduate School of Business and an undergraduate degree from Edmund A. Walsh School of Foreign Service. |
| Michael P. Mason | Currently, Michael P. Mason occupies the position of Treasurer, Chief Financial & Accounting Officer of Karyopharm Therapeutics, Inc. In the past Mr. Mason held the position of Treasurer & Vice President-Finance at Alnylam Pharmaceuticals, Inc., Chairman of Invesco Perpetual Select Trust Plc, Principal at KPMG LLP and Controller at Praecis Pharmaceuticals, Inc. He received an MBA from Babson College and an undergraduate degree from Stetson University. |
| Mikael Dolsten | Mikael Dolsten is on the board of New York Academy of Sciences, Karyopharm Therapeutics, Inc. and PhRMA Foundation and Chief Scientific Officer for Pfizer Inc., Member of Royal Swedish Academy of Engineering Sciences and Member of Government-University-Industry Research Roundtable. In his past career he occupied the position of Principal at OrbiMed Advisors LLC and Partner at OrbiMed Advisors Private Equity (a subsidiary of OrbiMed Advisors LLC), President of Wyeth Research, EVP, Global Head-Pharma Research & Discovery at Boehringer Ingelheim Pharmaceuticals, Inc., Member-Benefits, Law & Regulatory Committee at Wyeth Pharmaceuticals LLC and Senior Vice President at Wyeth Corp. He received a doctorate from the University of Lund. |
| Ian Karp | Presently, Ian Karp occupies the position of Vice President-Investor & Public Relations at Karyopharm Therapeutics, Inc. In the past Mr. Karp held the position of Senior Director-Global Marketing at Medimmune, Inc. and Head-Investor Relations of Shire Plc. Mr. Karp received an undergraduate degree from Emory University and an MBA from Rutgers Business School. |
| Mansoor Raza Mirza | Mansoor Raza Mirza is President-Elect & Executive Director at Nordic Society of Gynecologic Oncology, Chief Oncologist-Oncology Department at Copenhagen University Hospital, Member of The Gynecologic Oncology Group, Member of International Gynecologic Cancer Society, Member of European Society of Gynaecological Oncology, Member of European Society For Radiotherapy & Oncolog, Founding Executive Member at European Network of Gynecologic Oncology Trials Group and Member of American Society of Clinical Oncology and on the board of 5 other companies. Dr. Mirza received a graduate degree from the University of Southern Denmark and a doctorate from Russian State Medical University. |
| Ran Frenkel | Ran Frenkel founded Pfc Pharma Focus Israel Ltd. Mr. Frenkel is Chief Development Operations Officer at Karyopharm Therapeutics, Inc. and Vice President-Business Development of 2P2D Solutions Ltd. Mr. Frenkel previously occupied the position of Chief Executive Officer at Pfc Pharma Focus Israel Ltd., Managing Director-EMEA at Clinipace, Inc. and Managing Director at Actelion Pharmaceuticals US, Inc. He received an undergraduate degree from The Hebrew University of Jerusalem. |
| Brian Austad | Brian Austad is SVP-Pharmaceutical Sciences & Vendor Management at Karyopharm Therapeutics, Inc. In his past career he held the position of Director-Process Chemistry at Infinity Pharmaceuticals, Inc. and Scientist & Project Manager at Eisai Research Institute of Boston, Inc. He received a doctorate from the University of Wisconsin and an undergraduate degree from the University of Wisconsin-Eau Claire. |
| Kevin P. Malobisky | Presently, Kevin P. Malobisky occupies the position of Senior Vice President-Regulatory Affairs & Quality at Karyopharm Therapeutics, Inc. In his past career Dr. Malobisky was Global Head-Regulatory at Zafgen, Inc. Dr. Malobisky received a graduate degree from Temple University School of Pharmacy, a doctorate from Capella University and an undergraduate degree from The Pennsylvania State University. |
| Joan Wood | Joan Wood holds the position of Chief Human Resources Officer for Karyopharm Therapeutics, Inc. In her past career Ms. Wood was Vice President & Head-Human Resources at Sarepta Therapeutics, Inc. and Senior Vice President-Human Resources at Genzyme Corp. She received an undergraduate degree from the University of Saint Joseph and a graduate degree from Boston University. |
| Ran Frenkel | Ran Frenkel founded Pfc Pharma Focus Israel Ltd. Mr. Frenkel is Chief Development Operations Officer at Karyopharm Therapeutics, Inc. and Vice President-Business Development of 2P2D Solutions Ltd. Mr. Frenkel previously occupied the position of Chief Executive Officer at Pfc Pharma Focus Israel Ltd., Managing Director-EMEA at Clinipace, Inc. and Managing Director at Actelion Pharmaceuticals US, Inc. He received an undergraduate degree from The Hebrew University of Jerusalem. |
| Joan Wood | Joan Wood holds the position of Chief Human Resources Officer for Karyopharm Therapeutics, Inc. In her past career Ms. Wood was Vice President & Head-Human Resources at Sarepta Therapeutics, Inc. and Senior Vice President-Human Resources at Genzyme Corp. She received an undergraduate degree from the University of Saint Joseph and a graduate degree from Boston University. |
| Ran Frenkel | Ran Frenkel founded Pfc Pharma Focus Israel Ltd. Mr. Frenkel is Chief Development Operations Officer at Karyopharm Therapeutics, Inc. and Vice President-Business Development of 2P2D Solutions Ltd. Mr. Frenkel previously occupied the position of Chief Executive Officer at Pfc Pharma Focus Israel Ltd., Managing Director-EMEA at Clinipace, Inc. and Managing Director at Actelion Pharmaceuticals US, Inc. He received an undergraduate degree from The Hebrew University of Jerusalem. |
| Ian Karp | Presently, Ian Karp occupies the position of Vice President-Investor & Public Relations at Karyopharm Therapeutics, Inc. In the past Mr. Karp held the position of Senior Director-Global Marketing at Medimmune, Inc. and Head-Investor Relations of Shire Plc. Mr. Karp received an undergraduate degree from Emory University and an MBA from Rutgers Business School. |
| Jatin Shah | Dr. Jatin Shah, MD, is a Chief Medical Officer & Executive Vice President at Karyopharm Therapeutics, Inc. He received his undergraduate degree from The Ohio State University, an undergraduate degree from The Ohio State University College of Medicine and a doctorate degree from The Ohio State University. |
| Perry Monaco | Currently, Perry Monaco occupies the position of Senior Vice President-Sales for Karyopharm Therapeutics, Inc. |
| Ronit Milstein | Ms. Ronit Milstein is a Vice President-Operations at Karyopharm Therapeutics, Inc. |
abu_quant
扫一扫关注阿布量化
热门推荐
全部评论 0
暂无评论